

**Atty Docket No. 10282-1US**

## DECLARATION FOR UTILITY PATENT APPLICATION

**As a below named inventor, I hereby declare that:**

**My residence, post office address and citizenship are as stated below next to my name.**

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled

## METHOD OF PRODUCING VACCINES FORM PROTEIN SIGNAL OLIGOPEPTIDES

**[X] The specification of which is attached hereto.**

☐ The specification of which was filed on \_\_\_\_\_ as part of application no. \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information that is material to the patentability of the invention as claimed in this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**Application Ser. No.**  
**PCT/US95/00575**

Country  
PCT

Day/Month/Year Filed  
January 12, 1995

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 that occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Ser. No.

**Filing Date**

**Status:**

08/704,499

**August 28, 1996**

**Pending**

08/182,248

**January 14, 1994**

**Abandoned**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Matthias Rath, M.D.

Inventor's signature: [Signature]

Date: July 17, 1971

**Residence:** RA Almelo, The Netherlands

**Citizenship:** Germany

**Post Office Address:** Ambachtstraat 20, 7809 RA Almelo, The Netherlands

05/24/2001

15:01

KENYON - KENYON - #119572 H:4009869-103

NO. 587

1/23

PATENT  
11957/2**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of : Matthias RATH  
Serial No. : 09/232,186  
Filing Date : January 14, 1999  
For : METHOD OF PRODUCING VACCINES FROM PROTEIN  
SIGNAL OLIGOPEPTIDES

Assistant Commissioner for Patents  
Washington, D.C. 20231

**POWER OF ATTORNEY BY INVENTOR  
(REVOCAION OF PRIOR POWERS AND APPOINTMENT OF NEW POWER)**

Sir:

I, Dr. Matthias Rath, sole inventor of the above-identified application, hereby revoke all powers of attorney previously given and appoint the following attorneys and/or agents to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Jeffrey M. Butler (Reg. No. 41,652)  
Richard L. DeLucia (Reg. No. 28,819)  
Siu Lo (Reg. No. 46,877)

All correspondence should be sent to:

Siu Lo  
Kenyon & Kenyon  
One Broadway  
New York, NY 10004

Direct calls to:

Telephone No. (212) 425-7200  
Facsimile No. (212) 425-5288

Date:

May 25, 2001

By:

Respectfully submitted,

Dr. Matthias Rath